Terumo India Launches Innovative Ultimaster Nagomi Drug-Eluting Stent for Coronary Artery Disease Treatment

The Ultimaster Nagomi stands out for its adaptability to arteries of varying sizes, ensuring a personalised approach to coronary treatments for a broader range of patients.

Terumo India, a leading medical device company, has unveiled Ultimaster Nagomi, a new-generation drug-eluting stent designed to address coronary artery disease.

The Ultimaster Nagomi stands out for its adaptability to arteries of varying sizes, ensuring a personalised approach to coronary treatments for a broader range of patients. 

The stent's design allows for smooth navigation through complex arteries, making it a significant addition to the evolving landscape of coronary treatments.

Commenting on the same, Shishir Agarwal, president and managing director of Terumo India, said, "Our aim is to bring cutting-edge Japanese technologies to the service of Indian patients, providing them access to the latest innovations in healthcare."

Terumo, a global medical device company founded in 1921 in Japan, operates in over 160 countries, contributing to global healthcare solutions. 

In the same vein, the company introduced therapy devices, such as Occlusafe and LifePearl, aimed at helping patients manage liver cancer more effectively.

Occlusafe, based on Terumo's Balloon-TACE (B-TACE) therapy, offers a precise and targeted delivery of chemotherapy drugs to liver tumors while minimising damage to healthy tissues. This approach has shown improved response rates, reducing the need for repeat treatments and potentially preserving liver function.

Another notable addition is LifePearl, a solution that releases chemotherapeutic drugs in a controlled and sustained manner at the targeted tumor site within the liver. 

These developments are expected to improve clinical outcomes for liver cancer patients treated with TACE.
In a parallel development in cardiovascular care, the National Heart Centre Singapore (NHCS) has collaborated with US-based Medera's Novoheart to pioneer the creation of the world's first Asian patient-specific miniature human heart model with heart failure, known as the "Human Heart-in-a-Jar."

This venture utilises cell samples from Asian patients sourced from NHCS Biobank, a repository of anonymised biospecimens and clinical data from cardiovascular disease patients. 

Leveraging Novoheart's bioengineering technologies, the collaboration aims to create Asian patient-specific mini-heart models replicating key features observed in individuals with heart failure with preserved ejection fraction (HFpEF).

In another development in cardiac care, US-based Biotricity Inc. specialising in remote cardiac monitoring within consumer healthcare has filed a patent application for its Biotres device. The compact patch-form factor device addresses a crucial market gap, providing multiple ECG channels, diverse sensors, rechargeability, and connectivity.

Capable of recording up to 30 days, the Biotres device offers wireless connectivity for automated data offloading and remote ECG views, effectively minimising result wait times.